3-Benzyladenine

3-Benzyladenine

SCHEMBL5352368

Nc1ncn(Cc2ccccc2)c2ncnc1-2

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.56
PI4KA P42356 1/20 0.56
PI4K2B Q8TCG2 1/20 0.56
PI4K2A Q9BTU6 1/20 0.56
PI4KB Q9UBF8 1/20 0.56
TNF P01375 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
LMNA P02545 1/20 0.45
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DAPK1 P53355 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21121625 0.86 ADORA2A (0.41) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121744 0.86 SMN1; SMN2 (0.47) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121959 0.86 KCNH2 (0.44) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121674 0.86 ACP1 (0.47) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121650 0.85 ADORA2A (0.40) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121682 0.85 PKM (0.43) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121610 0.84 PKM (0.43) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121839 0.83 L3MBTL1 (0.44) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121702 0.83 ADORA2A (0.40) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL21121814 0.82 ALDH1A1 (0.47) ADORA2API4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3737683-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2020-11-18 EP claimed
US-20200338084-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2020-10-29 US claimed
WO-2019136093-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2019-07-11 WO claimed
EP-3737683-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2020-11-18 EP disclosed
US-20200338084-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2020-10-29 US disclosed
WO-2019136093-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2019-07-11 WO disclosed
WO-2014083327-A1 ADENINE DERIVATIVES SUITABLE FOR THE TREATMENT OF (INTER ALIA) MUSCULAR DYSTROPHY MD PHARMA AB (SE) 2014-06-05 WO disclosed
US-7256326-B2 Genetic engineering salt tolerance in crop plants BLUMWALD EDUARDO 2007-08-14 US disclosed
US-7250560-B2 Increasing salt tolerance in plants by overexpression of vacuolar NA+/H+ transporters BLUMWALD EDUARDO 2007-07-31 US disclosed
US-7244878-B2 Increasing salt tolerance in plants by overexpression of vacuolar Na+ /H+ transporters BLUMWALD EDUARDO 2007-07-17 US disclosed
US-7041875-B1 Genetic engineering salt tolerance in crop plants BLUMWALD EDUARDO 2006-05-09 US disclosed
US-5831092-A Process for producing purine derivatives AJINOMOTO CO., INC. (JP) 1998-11-03 US disclosed
US-5750871-A CULTURE PRODUCT CALGENE, INC. (US) 1998-05-12 US disclosed
EP-0728757-A1 Process for producing purine derivatives Ajinomoto Co., Inc. (JP) 1996-08-28 EP disclosed
US-5463174-A Expression cassette; oncogene-free cells; capable of regeneration to morphologically normal whole plants CALGENE INC. (US) 1995-10-31 US disclosed
EP-0270615-B1 TRANSFORMATION AND FOREIGN GENE EXPRESSION IN $i(BRASSICA) SPECIES CALGENE, INC. (US) 1993-08-04 EP disclosed
US-5188958-A Genetically engineered cells capable of regenerating normal whole plants with altered phenotypes CALGENE, INC. (US) 1993-02-23 US disclosed
EP-0270615-A4 TRANSFORMATION AND FOREIGN GENE EXPRESSION IN -i(BRASSICA) SPECIES. CALGENE INC (US) 1989-11-07 EP disclosed
EP-0270615-A1 TRANSFORMATION AND FOREIGN GENE EXPRESSION IN -i(BRASSICA) SPECIES. CALGENE INC (US) 1988-06-15 EP disclosed
WO-1987007299-A1 TRANSFORMATION AND FOREIGN GENE EXPRESSION IN BRASSICA SPECIES CALGENE, INC. (US) 1987-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200338084-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF ACP1, PTPRCAP, PTPRO ADORA2A 4746/4885PI4KA 148/4885PI4K2B 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.